Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Week in Review: China Pharmas Make Cross-Border Deals with the West

publication date: Dec 7, 2013
 | 
author/source: Richard Daverman, PhD

Deals and Financings

Hebei Medical University Biomedical Engineering Center (HMUBEC) in-licensed China rights to a pre-clinical cancer treatment from Sareum Holdings plc of Britain (AIM: SAR) (see story). HMUBEC is part of Hebei Medical University Science & Technology General Company, the commercial arm of the university with labs, manufacturing facilities and sales/distribution channels. Since its founding in 1992, the company has developed more than 85 therapeutic products and medical devices for China’s market.

JHL Biotech of Taiwan struck a non-exclusive deal with Switzerland’s Selexis SA to offer the latter company’s mammalian cell line technology (see story). The agreement will allow JHL to provide its clients with complete biologic process development and cGMP manufacturing services. JHL is building a commercial-scale biologic manufacturing facility in Wuhan, which it says will have the largest capacity in China. The company’s goal is to provide China and Asia with high-quality, low-cost biologic drugs.

Beijing Union Medical and Pharmaceutical, a subsidiary of the Chinese Academy of Medical Sciences, signed a Memorandum of Understanding with IXICO plc, a British company specializing in neuroimaging infomatics (see story). UMP will use IXICO’s neuroimaging informatics platform in China to diagnose dementia and use imaging biomarkers to evaluate new dementia treatments.

China Pioneer Pharma (HK: 1345) expanded its China distribution agreement with NovaBay Pharma (NYSE: NBY), a California company that is developing non-antibiotic antimicrobial products (see story). Pioneer will distribute two additional products in China and Southeast Asia for NovaBay. In return for these rights, Pioneer will purchase 5 million shares of NovaBay at a price of $5.7 million, replacing an earlier $3 million agreement.

Zhejiang Hisun Pharma (SHA: 600267) will raise at least 2 billion RMB ($328 million) in a private placement (see story). The company will offer up to 139.5 million new shares at a price not lower than 14.26 RMB per share (current price is 17.22 RMB). Hisun will use the money to build facilities for three projects: facilities for solid preparations and injections, solid preparation cancer treatments and the Phase II of its biopharmaceutical initiative.

Company News

Helsinn Group, a Swiss pharma that specializes in supportive cancer care, has opened a China representative office in Beijing (see story). The company in-licenses products (drugs, medical devices and nutritional supplements), which it develops until they are approved, and then out-licenses the products to partners for distribution and sales. Helsinn hinted that the China office will look for new products, saying it hopes to form alliances with China’s scientific community.

Disclosure: none.


 

Share this with colleagues:

 

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital